Docetaxel population pharmacokinetic modelling and simulation in Chinese cancer patients.

ABSTRACT:

Background

Docetaxel is a widely prescribed cytotoxic chemotherapy drug for various cancers and the main dose-limiting toxicity is dose-dependent neutropenia. In China, the current dose regimen for docetaxel frequently results in high inter-individual pharmacokinetic (PK) variability. There is a very urgent need to establish a population PK model of docetaxel for Chinese cancer patients, to predict the area under the curve (AUC) based on the PK model and avoid toxicity, providing optimal drug dose guidance to clinicians.

Methods

Docetaxel was administered at a dose of 75 mg/m² once every 3 weeks, and at the scheduled time, blood samples were collected to measure the docetaxel concentration. A nonlinear, mixed-effects modelling approach was used to fit the plasma c

SUBMITTER: Wei J 

PROVIDER: S-EPMC9279759 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature